Renovos Biologics has received breakthrough designation for a synthetic nanoclay gel scaffold designed to support localized bone formation.

The Food and Drug Administration granted breakthrough status to a product, Renovite BMP-2, that Renovos sees as an alternative to bone graft materials for interbody spinal fusion.

Medtech company Biocomposites invested in Renovos last year to help fund pre-market approval in spine, trauma and orthopedics applications.